BridgeBio Pharma, Inc. — News

Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year.

fool.com - 2026-08-02 05:55:00

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-28 11:06:46

Affinity Asset Advisors LLC cut its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 53.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company's stock after selling 170,000 shares during the quarter.

defenseworld.net - 2026-07-25 04:05:31

California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 21.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 253,479 shares of the company's stock after acquiring an additional 45,596 shares during the period. California Public Employees Retirement System

defenseworld.net - 2026-07-24 04:11:26

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.

zacks.com - 2026-07-23 14:16:15

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockbuster opportunity for BridgeBio - Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile - BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase 3 registrational study of encaleret in chronic hypoparathyroidism later this summer; successful development could extend encaleret's utility to a broader patient population PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1).

globenewswire.com - 2026-07-22 07:30:00

Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 10.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 889,356 shares of the company's stock after selling 104,864 shares during the quarter. Allspring Global Investments Holdings

defenseworld.net - 2026-07-18 03:11:15

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

marketbeat.com - 2026-07-13 12:25:30

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market.

seekingalpha.com - 2026-07-12 09:55:00

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

globenewswire.com - 2026-07-10 16:01:00

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.

zacks.com - 2026-07-10 13:25:26

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com - 2026-07-10 06:36:04

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.

zacks.com - 2026-07-08 13:31:08

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.

zacks.com - 2026-07-08 13:25:34

BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.

zacks.com - 2026-07-08 13:25:32

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P

globenewswire.com - 2026-07-02 07:30:00

- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company's 30-day VWAP)

globenewswire.com - 2026-07-01 07:30:00

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p

globenewswire.com - 2026-06-28 16:00:00

PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on June 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 30 new employees in restricted stock units for an aggregate of 66,810 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

globenewswire.com - 2026-06-23 16:31:00

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children's Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026.

globenewswire.com - 2026-06-22 07:30:00

Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was "Welcome back, my friends to the show that never ends." On cue, the never-say-die stock market shook off early worries and all the major indices closed higher on Tuesday. Like the proverbial broken record, the S&P 500... Here Are Wednesday's Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More

247wallst.com - 2026-06-03 13:08:00

- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community

globenewswire.com - 2026-05-27 07:30:00

BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company's transthyretin amyloid cardiomyopathy (ATTR-CM) franchise.

247wallst.com - 2026-05-19 12:15:16

BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company's late-stage pipeline.

marketbeat.com - 2026-05-13 01:04:58

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 00:20:43

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and key secondary efficacy endpoints were met in the Phase 3 CALIBRATE trial; 76% of participants administered encaleret achieved both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p<0.

globenewswire.com - 2026-05-12 07:30:00

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1

globenewswire.com - 2026-05-12 07:30:00

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

globenewswire.com - 2026-05-11 09:30:00

PALO ALTO, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock.

globenewswire.com - 2026-05-08 16:01:00

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

globenewswire.com - 2026-05-08 16:01:00

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 11:31:17

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.88 per share a year ago.

zacks.com - 2026-05-07 18:26:10

PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress.

globenewswire.com - 2026-05-07 16:01:00

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

globenewswire.com - 2026-05-06 16:01:00

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including:

globenewswire.com - 2026-05-06 07:30:00

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting.

globenewswire.com - 2026-05-05 07:30:00

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026.

globenewswire.com - 2026-05-04 07:30:00